Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

Gout Clinical Trial

Official title:

A Phase 2B Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of 3 Dosages of SAP-001 in Combination With Standard of Care in Adult Subjects With Gout

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05690204
• Other study ID #: SAP001-202
• Status: Recruiting
• Phase: Phase 2
• Start date: December 12, 2022
• Est. completion date: January 30, 2025

Study information

• Verified date: August 2023
• Source: Shanton Pharma Co., Ltd.
• Contact: Carmen Arencibia
• Phone: 9178067229
• Email: carmen.arencibia[@]shantonpharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to confirm the safety and pharmacological characteristics of SAP-001, evaluate its efficacy in lowering sUA and tophus burden, and identify the appropriate dose regimen for future studies in adult subjects with gout, with or without tophi, and hyperuricemia refractory to SoC XOI therapy.

Description:

A Phase 2B, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to assess the safety, PK, PD, and efficacy of 3 orally administered dosages of SAP-001 (10 mg QD, 30 mg QD, and 60 mg QD) compared to placebo QD in adult subjects with gout, with or without tophi, and hyperuricemia refractory to standard-of-care (SoC) XOI therapy. In the completed Phase 1 and Phase 2 studies, SAP-001 was well tolerated at single doses up to 120 mg and at dosages up to 60 mg QD for 28-days in subjects with gout and hyperuricemia and demonstrated statistically significant reductions in sUA levels compared to placebo. The aim of this study is to confirm the safety and pharmacological characteristics of SAP-001

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: January 30, 2025
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Main Inclusion Criteria:

1. Male or female, =18 and =75 years of age, willing and able to provide informed consent and to adhere to the requirements and guidelines of the protocol.

2. Body mass index =19 and =40 kg/m2 at the Screening Visit (Visit 1).

3. Already have been diagnosed with gout according to the current American College of Rheumatology (ACR) scoring criteria for the classification of primary gout; or has symptoms of gout with at least 1 of the following: i. 3 gout flares in the previous 18 months prior to screening; or ii. Presence of at least 1 gout tophus; or iii. Current diagnosis of gouty arthritis; Subject must be refractory to SoC XOI therapy, or in whom XOI is contraindicated. Refractory to SOC XOI is defined by a medical history of failure to normalize sUA to <6 mg/dL (the ACR target for gout) with at least 3 months of SoC XOI treatment at the maximum medically appropriate dose. XOI contraindication can be self-reported medical contraindication to SoC XOI therapy or in whom SoC XOI therapy is not considered medically appropriate treatment for symptomatic gout. Subject can still participate in the clinical trial if SOC XOI therapy is considered medically not appropriate or contraindicated.

4. Subject must have been on SoC XOI therapy for gout and hyperuricemia for at least 4 weeks immediately before the Randomization Visit (Day 1, Visit 4) unless SoC XOI therapy is contraindicated or not medically appropriate. Subjects who stopped SoC XOI therapy within 4 weeks of the Screening Visit are eligible for the study but must be restarted on SoC XOI therapy and confirmed resistant to XOI therapy (sUA levels =7.0 mg/dL) after at least 4 weeks of treatment.

5. Subject must have sUA levels =7.0 mg/dL by central laboratory results at the Screening Visit (Visit 1) and prior to randomization at the Randomization Visit (Day 1, Visit 4).

Main Exclusion Criteria:

1. Subjects not previously diagnosed as having gout before the Screening Visit.

2. Female subject is pregnant, planning to get pregnant, lactating/breastfeeding, or has a positive urine pregnancy test at the Screening Visit or prior to randomization at the Randomization Visit (Day 1, Visit 4).

3. Subject has used any prescription drugs (eg, losartan, pegloticase, URAT1 inhibitors), OTC medications, herbal medications or products, vitamins, or minerals that are known to lower sUA levels (except SoC XOI therapies) within 14 days prior to the Randomization Visit (Day 1, Visit 4). Exceptions may be made on a case-by-case basis (such as chronic use of low dose aspirin) following discussion and agreement between the investigator and sponsor. Subjects who are already taking losartan for blood-pressure control are allowed to enroll in the study and continue taking losartan if they have been on a stable dose for at least 6 months.

4. Subject was not compliant with taking placebo during the Run-in Period (defined as taking <80% or >120% of planned placebo doses) or the investigator determines that the subject was not compliant with SoC XOI gout medications (unless SoC XOI therapy is contraindicated or not medically appropriate) during the Run-in Period as assessed prior to randomization at the Randomization Visit (Day 1, Visit 4).

5. Subject had an acute gout flare (exclusive of symptomology associated with chronic synovitis/arthritis) that did not resolve at least 14 days prior to the Randomization Visit (Day 1, Visit 4). If an acute gout flare occurs during the Screening or Run-in Periods, the subject may be rescreened after a period of at least 14 days has passed following resolution of the flare.

6. Serum creatinine level >1.5 mg/dL and/or eGFR =60 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation23 by central laboratory results at the Screening Visit (Visit 1) or prior to randomization at the Randomization Visit (Day 1, Visit 4).

Related Conditions & MeSH terms

• Gout

Intervention

Drug:
• SAP001
Test the efficacy and safety of SAP 001 versus placebo

Locations

Country	Name	City	State
Puerto Rico	Puerto Rico Site	San Juan
United States	Idaho Site	Boise	Idaho
United States	Florida Site	DeBary	Florida
United States	Denver Site	Denver	Colorado
United States	Mississippi Site	Jackson	Mississippi
United States	Texas Site	Mesquite	Texas
United States	Florida Site	Miami	Florida
United States	Florida Site	Miami Lakes	Florida
United States	Florida Site	Miami Lakes	Florida
United States	Maryland Site	Oxon Hill	Maryland
United States	Texas Site	Plano	Texas
United States	North Carolina Site	Raleigh	North Carolina
United States	California Site	Sacramento	California
United States	California Site	San Diego	California
United States	Texas Site	The Woodlands	Texas
United States	Florida Site	Winter Park	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Shanton Pharma Co., Ltd.

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	primary	assess the proportion of subjects who achieved sUA levels less than 6 mg/dl by laboratory results	24 weeks
Secondary	AE	Incidence of AEs including SAE and TEAEs by CTCAE criteria	24 weeks
Secondary	Change from Baseline on PE measure	Changes from baseline in Physical Exam based on number of participants with abnormal findings	24 weeks
Secondary	Changes from Baseline on ECGs	Changes from baseline in ECG parameters by QTc intervals	24 weeks